Biotechnology Responsible Research Conduct Law In Russia.
1. Introduction
Responsible Research Conduct in biotechnology in Russia refers to the legal, ethical, scientific and institutional standards governing how biotechnology research is designed, funded, conducted, supervised, documented and published.
It seeks to ensure that biotechnology research:
Protects human dignity, life, health and individual autonomy.
Prevents scientific fraud, fabrication, falsification and plagiarism.
Ensures ethical treatment of research participants and laboratory animals.
Regulates genetic engineering and genetically modified organisms (GMOs).
Protects genetic information and confidential biological data.
Prevents unauthorized use, transfer or commercialization of biological materials.
Establishes accountability for researchers, laboratories, universities, sponsors and biotechnology companies.
Russia does not have one comprehensive statute entitled the Responsible Biotechnology Research Conduct Act. Instead, responsible conduct is governed by several overlapping legal instruments, including constitutional provisions, health legislation, scientific research legislation, genetic engineering regulations, personal-data protection rules, civil liability and criminal law.
The distinction between binding legal obligations, institutional research-ethics standards and international scientific principles is important when evaluating Russian biotechnology law.
2. Constitutional and statutory framework
A. Constitution of the Russian Federation
The Russian Constitution provides the foundation for responsible biotechnology research.
Important provisions include:
| Provision | Legal significance |
|---|---|
| Article 20 | Protection of the right to life |
| Article 21 | Protection of human dignity and prohibition of treatment incompatible with human dignity |
| Article 23 | Protection of privacy and personal and family secrets |
| Article 24 | Restrictions on collecting, storing, using and disseminating personal information without lawful grounds |
| Article 41 | Right to health protection and medical care |
| Article 42 | Right to a favourable environment and reliable information about its condition |
| Article 44 | Protection of intellectual property and scientific creativity |
These constitutional provisions influence the legality of genetic experiments, human biological sampling, clinical trials and biotechnology commercialization.
B. Federal Law No. 127-FZ of 23 August 1996 – On Science and State Scientific and Technical Policy
This is one of the principal laws governing scientific research in Russia.
Article 3 establishes the legal position of participants in scientific and scientific-technical activities.
Important responsibilities of scientific workers include:
Conducting scientific and experimental research without violating human rights and freedoms.
Avoiding harm to human life and health.
Protecting the environment.
Objectively evaluating scientific programmes, projects and research results.
Maintaining professional standards in scientific activities.
Respecting the legal rights of other researchers and institutions.
The law also recognises the researcher's right to refuse participation in scientific research that negatively affects human beings, society or the environment.
Application to biotechnology: A genetic engineering researcher cannot justify an unsafe experiment merely because it may produce commercially valuable scientific results.
For example, a research institution conducting experimental gene-editing research must consider potential biological risks, human safety and environmental consequences.
rostransnadzor.gov.ru+1
C. Federal Law No. 86-FZ of 5 July 1996 – On State Regulation in the Field of Genetic Engineering Activities
Core biotechnology legislation
This law is particularly important for responsible research conduct involving genetic engineering.
It regulates activities involving genetic manipulation, genetically engineered organisms and associated environmental and public-health risks.
Important provisions:
Article 1: Defines the scope of genetic engineering regulation, including environmental protection, ecological safety and human health protection.
Article 5: Establishes regulatory principles concerning human safety, environmental safety, information about safety and registration of relevant genetically modified organisms and products.
Article 6: Identifies activities involving genetic engineering, including genetic manipulation, testing of genetically engineered organisms and disposal of associated waste.
Article 11: Requires applicable products and services to satisfy mandatory environmental, public-health, pharmacopoeial and other legal requirements.
Article 12: Establishes liability for harm caused through genetic engineering activities and specified regulatory violations.
Importantly, Article 6 provides that closed-system genetic engineering activities involving risk levels III and IV are subject to licensing.
CIS Legislation+3
Example: A Russian biotechnology laboratory developing genetically modified microorganisms must comply with the applicable biosafety and licensing requirements. It must also maintain appropriate laboratory controls and ensure that biological waste is properly managed.
D. Federal Law No. 323-FZ of 21 November 2011 – On the Fundamentals of Health Protection of Citizens in the Russian Federation
This law regulates medical research where biotechnology activities involve human health.
Article 20 establishes the principle of informed voluntary consent to medical intervention.
Under this framework:
Patients must receive understandable information about proposed medical interventions.
Relevant risks and expected consequences must be explained.
Consent must be voluntary.
Patients generally retain the right to refuse or terminate medical intervention.
Special rules apply to minors and persons unable to provide legally effective consent.
Article 36.1 is also relevant to biomedical cell products and their clinical application.
Application: Researchers conducting stem-cell-related medical research, cellular therapy investigations or other biomedical interventions must observe applicable medical and clinical regulatory requirements.
static-0.minzdrav.gov.ru+1
E. Federal Law No. 61-FZ of 12 April 2010 – On the Circulation of Medicines
This law is important when biotechnology research involves experimental medicinal products, biological medicines, vaccines and gene-based pharmaceutical development.
Articles 21–23 establish requirements concerning permission and organisation of clinical trials.
Article 43 – Rights of patients participating in clinical trials
The principal protections include:
Voluntary participation.
Written information about the medicinal product.
Disclosure of expected efficacy and potential risks.
Information about the duration and conditions of the trial.
Confidentiality protections.
The right to withdraw from participation.
Additional protections for vulnerable groups.
Article 44 – Compulsory insurance
Organisations conducting clinical trials must comply with the statutory requirements concerning compulsory life and health insurance for participating patients.
These provisions make clinical-trial accountability an important part of responsible biotechnology research.
WIPO
F. Federal Law No. 152-FZ of 27 July 2006 – On Personal Data
Biotechnology research frequently involves highly sensitive information, including:
DNA sequences.
Genetic predispositions.
Biological samples linked to individuals.
Medical histories.
Genomic sequencing results.
Hereditary disease information.
The law establishes rules governing lawful processing, confidentiality, security and disclosure of personal data.
Genetic and medical information may also engage the special-category personal-data protections under Article 10.
Researchers and biotechnology institutions must therefore establish appropriate legal grounds for collecting, processing, storing and transferring identifiable research data.
The February 2026 amendments to Federal Law No. 86-FZ further strengthen the statutory treatment of human genetic data and their transfer.
CIS Legislation+1
3. Core principles of responsible biotechnology research conduct
3.1 Scientific integrity
Scientific integrity requires researchers to report findings honestly and maintain reliable research records.
Prohibited or professionally unacceptable practices include:
Fabrication of experimental results.
Falsification of laboratory observations.
Manipulation of genomic sequencing results.
Selective suppression of adverse findings.
Plagiarism.
Misrepresentation of research authorship.
Falsification of clinical-trial documentation.
For example, a researcher who deliberately changes genetic sequencing results to make an experimental treatment appear successful may face institutional disciplinary action and, depending on the circumstances, civil or criminal liability.
Importantly, not every breach of research integrity automatically constitutes a criminal offence. Criminal liability requires the elements of a specific offence.
3.2 Informed consent and human dignity
Research involving human biological material must respect applicable consent, privacy and medical-law requirements.
Researchers should explain:
The purpose of the study.
The nature of the biological sample required.
Potential risks.
Whether genetic testing will be conducted.
How research data will be used.
Whether samples may be stored for future research.
Whether information may be shared with other institutions.
Consent for a medical intervention and lawful grounds for processing personal data are related but legally distinct matters.
3.3 Biosafety and environmental protection
Responsible conduct also requires effective biological-risk management.
Research institutions should implement:
Appropriate containment facilities.
Biological-risk assessment.
Laboratory access controls.
Personnel training.
Safe handling of genetically modified organisms.
Waste-disposal procedures.
Emergency response arrangements.
Monitoring of accidental biological releases.
The obligations are particularly important for genetic engineering involving microorganisms, viruses, transgenic animals and genetically modified plants.
3.4 Animal research ethics
Biotechnology research may involve experimental animals, including mice, rats and other laboratory species.
Responsible research requires compliance with applicable Russian veterinary, animal-welfare, sanitary and institutional requirements.
The relevant ethical considerations include:
Scientific justification for animal use.
Reduction in the number of animals used.
Refinement of experimental procedures.
Minimisation of pain and distress.
Appropriate veterinary supervision.
The internationally recognised 3Rs principle—Replacement, Reduction and Refinement—is a useful ethical benchmark, but should not be confused with a single comprehensive Russian statutory code governing all laboratory animal research.
3.5 Research transparency and reproducibility
Responsible biotechnology research should maintain:
Accurate laboratory notebooks.
Research protocols.
Experimental records.
Quality-control reports.
Sequencing documentation.
Data-retention procedures.
Adverse-event reports.
Authorship and publication records.
Transparency must nevertheless be balanced against personal-data protection, trade secrets and legally protected scientific or state information.
4. Institutional responsibilities and regulatory supervision
Russian biotechnology research institutions have responsibilities beyond the conduct of individual scientists.
| Institution or authority | Relevant responsibility |
|---|---|
| Ministry of Science and Higher Education | Scientific policy and research institutions |
| Ministry of Health | Medical research and medicinal-product regulation |
| Roszdravnadzor | Oversight of healthcare and relevant medical activities |
| Rospotrebnadzor | Public-health and sanitary supervision |
| Rosselkhoznadzor | Veterinary and phytosanitary supervision |
| Research institutions | Internal scientific integrity and research governance |
| Institutional ethics committees | Ethical review within their applicable mandate |
Government Resolution No. 35 of 18 January 2023 establishes procedures for state registration of relevant genetically engineered organisms intended for environmental release and associated products.
It also identifies monitoring and supervisory responsibilities of relevant authorities.
CIS Legislation+1
Internal institutional governance
A biotechnology institution should establish an effective internal compliance system that includes:
Research ethics review.
Biosafety committees.
Conflict-of-interest declarations.
Research misconduct investigation procedures.
Data protection policies.
Laboratory inspection systems.
Whistleblower reporting mechanisms.
Corrective and disciplinary measures.
An ethics committee's approval does not exempt researchers from obtaining regulatory permissions or complying with statutory requirements.
5. Important case laws relating to responsible biotechnology research in Russia
Russian reported judicial decisions specifically addressing scientific misconduct in genetic engineering are limited. However, several important judgments establish principles relevant to research safety, informed consent, biological evidence, privacy and institutional accountability.
Case 1. Traskunova v. Russia (2022)
Most relevant clinical-research judgment
Citation: Traskunova v. Russia, Application No. 21648/11, European Court of Human Rights, Judgment of 30 August 2022.
Facts:
The case concerned a woman suffering from schizophrenia who participated in clinical trials of an experimental medicine called asenapine.
She participated in two consecutive clinical trials. During the second trial, she suffered cardiac and respiratory arrest and subsequently died.
Her mother challenged the failure of medical professionals to adequately examine and monitor her daughter's health.
The investigation revealed serious concerns, including:
Inadequate pre-trial medical examinations.
Insufficient monitoring during the trials.
Failure to properly consider existing cardiovascular risks.
Concerns about the practical implementation of informed-consent safeguards.
Inadequate investigation of the circumstances surrounding the death.
Legal issue:
Whether Russia had fulfilled its positive obligations under Article 2 of the European Convention on Human Rights, which protects the right to life.
Judgment:
The European Court of Human Rights found a violation of Article 2.
It concluded that Russia had failed to ensure the effective implementation of its regulatory framework for clinical trials and had not provided an adequate judicial response.
Legal principles established:
Experimental medical research requires effective safety supervision.
Regulatory approval alone does not guarantee responsible research conduct.
Participants must receive meaningful protection throughout a clinical trial.
Vulnerable participants require particularly strong safeguards.
Authorities must investigate failures to comply with clinical-trial protections effectively.
Importance for biotechnology law:
This judgment is highly relevant to gene therapy trials, experimental cell therapies, genomic medicine and biotechnology-based pharmaceutical research.
It demonstrates that researchers and institutions cannot rely solely on formal consent documents while ignoring the actual health and safety of research participants.
BAILII+2
Case 2. Kalacheva v. Russia (2009)
Citation: Kalacheva v. Russia, Application No. 3451/05, European Court of Human Rights, Judgment of 7 May 2009.
Facts:
The case concerned paternity proceedings in which a domestic court ordered DNA testing.
Biological samples were collected and sent to a specialised institution for forensic genetic examination.
The resulting report indicated a 99.99% probability of paternity.
The applicant challenged the domestic court's treatment of the genetic evidence and the fairness of the proceedings.
Legal significance:
The case illustrates the importance of procedural reliability when genetic testing is used in legal proceedings.
Its relevance to responsible biotechnology research includes:
Proper collection of biological samples.
Reliable laboratory examination.
Scientific accuracy of genetic testing.
Appropriate handling of expert evidence.
Judicial scrutiny of scientific conclusions.
Application to biotechnology research:
A research institution conducting DNA sequencing or genetic testing should maintain proper sample identification, documentation, analytical reliability and traceability.
A scientifically sophisticated result cannot automatically be treated as legally conclusive without examining the methodology and procedural reliability.
HUDOC
Case 3. Hristozov and Others v. Bulgaria (2012) – Comparative authority
Citation: Hristozov and Others v. Bulgaria, Applications Nos. 47039/11 and 358/12, European Court of Human Rights, Judgment of 13 November 2012.
This is not a Russian case, but it is relevant comparative jurisprudence concerning access to experimental medicines.
Facts:
The applicants were seriously ill cancer patients who sought access to an experimental medicinal product that had not received the required marketing authorisation.
Legal issue:
Whether the refusal to provide access to the experimental treatment violated their Convention rights.
Importance:
The judgment discusses the relationship between experimental medical treatment, patient autonomy, public-health regulation and state discretion.
Application to Russia:
It provides comparative guidance for Russian biotechnology institutions developing experimental cancer treatments, personalised medicines and advanced biological products.
It also illustrates why research participation, experimental treatment and ordinary authorised medical care must be legally distinguished.
BAILII
Case 4. General Russian scientific-fraud jurisprudence
Russian criminal law does not create one universal offence called scientific misconduct.
Instead, fraudulent conduct connected with research may fall under existing criminal provisions.
Relevant examples include:
| Criminal Code provision | Possible application |
|---|---|
| Article 159 | Fraud involving research grants or funding |
| Article 146 | Copyright infringement, including qualifying plagiarism-related conduct |
| Article 147 | Patent-related infringement |
| Article 272 | Unlawful access to computer information |
| Article 292 | Official-document forgery by an appropriate public official |
| Article 238 | Providing services or products that fail applicable safety requirements, where its elements are established |
An academic discussion of Russian scientific fraud describes a case involving university officials and research-contract funds. The court found that research work had not actually been performed and that false acceptance documents had been used to conceal the misappropriation of funds.
This is an example of how research-related financial fraud may be prosecuted under ordinary criminal law rather than a separate scientific-misconduct offence.
The case is not a biotechnology-specific precedent, and it should not be presented as one.
Группа компаний ИНФРА-М
6. Legal liability for irresponsible biotechnology research
Different forms of liability may arise depending on the nature of the violation.
A. Civil liability
Under Russian civil law, a researcher or biotechnology organisation may face civil claims where unlawful conduct causes damage.
Possible consequences include:
Compensation for personal injury.
Compensation for medical expenses.
Compensation for legally recognised moral harm.
Environmental damage compensation.
Compensation for intellectual-property infringement.
Contractual damages.
For example, if a laboratory negligently releases a harmful genetically modified organism and causes legally recognised environmental damage, the responsible parties may face compensation claims under the applicable environmental and civil-law framework.
B. Administrative liability
Administrative sanctions may arise from violations of licensing, sanitary, environmental, laboratory-safety, registration and other regulatory requirements.
Depending on the circumstances, consequences may include:
Administrative fines.
Suspension of relevant activities.
Regulatory orders.
Suspension or cancellation of applicable permissions.
Product restrictions or withdrawal.
C. Criminal liability
Criminal liability may arise when research misconduct involves conduct satisfying the elements of a criminal offence.
Examples include:
Fraudulent acquisition of research grants.
Deliberate falsification of official documents.
Unlawful appropriation of intellectual property.
Unlawful access to confidential genetic databases.
Serious unlawful conduct involving unsafe products or services.
Conduct causing death or injury where the requirements of an applicable criminal offence are satisfied.
An important distinction is that an incorrect experimental result, scientific disagreement or honest research error does not automatically establish criminal responsibility.
D. Institutional and professional liability
Universities, research institutes and biotechnology companies may also take internal action against researchers.
Possible measures include:
Withdrawal of research approval.
Suspension from laboratory work.
Termination of research contracts.
Retraction or correction of publications.
Disciplinary action.
Reporting suspected violations to competent authorities.
7. Responsible conduct in specialised biotechnology fields
| Biotechnology field | Responsible research requirement |
|---|---|
| CRISPR gene editing | Scientific validation, risk assessment and compliance with applicable genetic-engineering and medical laws |
| Stem-cell research | Lawful sourcing, consent and compliance with biomedical requirements |
| Human genome sequencing | Genetic-data protection and appropriate consent |
| Synthetic biology | Biosafety assessment and containment |
| Vaccine development | Clinical-trial authorisation, monitoring and participant protection |
| Genetically modified organisms | Registration, safety assessment and environmental controls |
| Artificial intelligence in biotechnology | Research-data integrity, privacy and accountability |
| Reproductive biotechnology | Protection of reproductive rights, consent and applicable medical regulations |
| Biological databases | Data security, lawful processing and confidentiality |
| Pharmaceutical biotechnology | Good Clinical Practice, quality controls and regulatory compliance |
8. International standards and their relevance to Russia
Responsible biotechnology research is also informed by international scientific and ethical instruments.
Important examples include:
1. Declaration of Helsinki (World Medical Association, 2024 revision)
Provides ethical principles for medical research involving human participants, including informed consent, independent ethics review and participant welfare.
2. UNESCO Universal Declaration on the Human Genome and Human Rights (1997)
Establishes international principles concerning human dignity, genetic information and the protection of individuals against genetic discrimination.
3. UNESCO Universal Declaration on Bioethics and Human Rights (2005)
Addresses informed consent, privacy, confidentiality, equality, human dignity and social responsibility.
4. International Council for Harmonisation – Good Clinical Practice (ICH-GCP)
Provides standards for clinical-trial design, conduct, documentation, monitoring and reporting.
These instruments have different legal statuses. They should not automatically be treated as directly enforceable Russian legislation. Their applicability depends on domestic implementation, regulatory requirements and the circumstances of the research.
9. Important developments in Russian biotechnology law in 2026
A significant development is Federal Law No. 43-FZ of 20 February 2026, which amended Federal Law No. 86-FZ.
The amendments became effective on 1 September 2026.
The changes are particularly relevant to responsible research conduct because they address:
The legal definition of human genetic data.
Genetic information obtained through molecular and genetic research.
Population genetic and immunological research.
Legal regulation of transfers of human genetic data.
Protection and preservation of genetic information.
Responsibility for violations involving genetic-data transfers.
The amendments also strengthen the connection between genetic engineering regulation and the protection of human genetic information.
Legal significance: Biotechnology institutions must consider not only the safety of genetic experiments but also the lawful collection, handling and transfer of genetic information.
CIS Legislation+1
10. Major legal challenges
Despite the existence of several regulatory instruments, responsible biotechnology research in Russia faces important legal challenges.
1. Fragmented legislation: Research ethics, clinical trials, genetic engineering and personal-data protection are regulated through different laws.
2. Scientific misconduct: There is no single comprehensive statutory framework establishing a uniform procedure for investigating every form of scientific misconduct.
3. Genetic-data protection: Increasingly sophisticated genomic research creates challenges involving consent, secondary use and international transfers.
4. Institutional independence: Effective research oversight requires appropriate independence and competence in institutional ethics and biosafety review.
5. Experimental-treatment liability: Determining responsibility when experimental biotechnology treatments cause unexpected injuries can involve complicated scientific and legal questions.
6. International research collaboration: Cross-border research requires compliance with Russian data, licensing, intellectual-property and applicable foreign regulatory requirements.
11. Recommendations for strengthening responsible research conduct
The following measures could improve the governance of Russian biotechnology research:
Introduce clearer statutory definitions of serious research misconduct.
Establish consistent procedures for investigating fabrication and falsification.
Strengthen independent ethics review.
Improve genetic-data protection and consent mechanisms.
Require documented biosafety assessments.
Establish transparent conflict-of-interest procedures.
Improve protection for research participants reporting misconduct.
Strengthen institutional accountability for research funding.
Introduce effective monitoring of biotechnology research after regulatory approval.
Improve international cooperation concerning research integrity.
12. Conclusion
Responsible Research Conduct Law in Russia is based on a combination of scientific regulation, medical law, genetic-engineering legislation, constitutional protections, personal-data law and civil and criminal liability.
Federal Law No. 127-FZ establishes important responsibilities for scientific workers, while Federal Law No. 86-FZ provides the principal framework for genetic engineering activities. Federal Laws Nos. 323-FZ and 61-FZ provide important protections for medical research participants.
The most significant judicial authority discussed in this area is Traskunova v. Russia (2022). It demonstrates that formal regulatory approval and written consent are insufficient if research institutions fail to implement actual safety protections.
Kalacheva v. Russia (2009) additionally illustrates the importance of reliable genetic evidence and proper scientific procedures.
The central legal principle is that scientific innovation must operate within the boundaries of human dignity, research integrity, informed consent, biological safety and legal accountability.
13. Key legislation and case-law reference list
| Legal authority | Subject |
|---|---|
| Russian Constitution, Articles 20, 21, 23, 24, 41 and 42 | Fundamental rights |
| Federal Law No. 127-FZ (1996) | Scientific research governance |
| Federal Law No. 86-FZ (1996) | Genetic engineering |
| Federal Law No. 323-FZ (2011) | Health protection |
| Federal Law No. 61-FZ (2010) | Medicinal products and clinical trials |
| Federal Law No. 152-FZ (2006) | Personal-data protection |
| Federal Law No. 43-FZ (2026) | Genetic-data amendments |
| Government Resolution No. 35 (2023) | GMO registration |
| Traskunova v. Russia (2022) | Clinical-trial safety and accountability |
| Kalacheva v. Russia (2009) | DNA evidence and procedural reliability |
| Hristozov and Others v. Bulgaria (2012) | Experimental medicines and patient rights |
Important jurisdictional qualification: The ECHR judgments discussed above are historical authorities. Russia ceased to be a party to the European Convention on Human Rights on 16 September 2022. The Court's jurisdiction over Russia is limited to acts or omissions capable of constituting Convention violations occurring before that date. The 2022 Traskunova judgment concerned earlier clinical-trial events.
For academic legal research, Traskunova should therefore be treated as an important historical judicial authority, not as evidence that the ECHR currently exercises general jurisdiction over Russian biotechnology regulation.
This is an academic legal overview, not a substitute for checking the official Russian-language statutory text and applicable implementing regulations.

comments